short seller
outstanding shares

July was an excellent month for global stock markets Historically, the S&P 500 takes about 19 months to recover from a bear market However, since 1982, if the bear market does… Provide specific products and services to you, such as portfolio management or data aggregation. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

stock

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data. CompareTWST’s historical performanceagainst its industry peers and the overall market. There may be delays, omissions, or inaccuracies in the Information. Zacks Earnings ESP looks to find companies that have recently seen positive earnings estimate revision activity. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.

Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Twist Bioscience Corporation Provides Earning Guidance for Full Fiscal Year 2022 and First Quarter of Fiscal 2022

52 week low is the lowest price of a stock in the past 52 weeks, or one year. Twist Bioscience Corp 52 week low is $12.17 as of April 29, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Twist Bioscience Corp 52 week high is $58.76 as of April 29, 2023. I’m long TWST and I’m bored trying to doodle with some ideas for this technical analysis. I have TWST trading sideways for the next few months before aiming for the previous ATH again.

This popular ETF stands apart from its peers with unusually large ownership of many stocks in its compact portfolio. The industry with the best average Zacks Rank would be considered the top industry , which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank would place in the bottom 1%. An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s. (10%) has been stable over the past year, but is still higher than 75% of US stocks.

In the past three months, Twist Bioscience insiders have not sold or bought any company stock. MarketBeat has tracked 10 news articles for Twist Bioscience this week, compared to 3 articles on an average week. Twist Bioscience has only been the subject of 2 research reports in the past 90 days. Measures how much net income or profit is generated as a percentage of revenue.

shares

Geographically, it derives a majority of its revenue from the United States. A valuation method that multiplies the price of a company’s stock by the total number of outstanding shares. The average analyst rating for TWST stock from 7 stock analysts is “Buy”.

Company Summary

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company’s DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

generated

Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers. Twist Bioscience updated its FY 2023 earnings guidance on Monday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $261.00 million-$269.00 million, compared to the consensus revenue estimate of $265.53 million. 21.26% of the outstanding shares of Twist Bioscience have been sold short. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

Dow Jones Network

It allows the user to better focus on the stocks that are the best fit for his or her personal trading style. Shares of Twist Bioscience Corp. were down 1.6% in premarket trading on Wednesday after the company said its in-vitro diagnostic test that can detect SARS-CoV-2 RNA received emergency authorization in the U.S. Twist Bioscience’s stock is owned by a number of institutional and retail investors.

The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California. Twist Bioscience Corporation is a synthetic biology and genomics company. The Company has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology.

  • Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
  • We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view.
  • It stands for Earnings before Interest, Taxes, Depreciation, and Amortization.
  • I’m long TWST and I’m bored trying to doodle with some ideas for this technical analysis.

The technique has proven to be very useful for finding positive surprises. As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

About the Company

The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The Style Scores are a complementary set of indicators to use alongside the Zacks Rank.

Does Twist Bioscience Corp (TWST) Have What it Takes to be in Your Portfolio Friday? – InvestorsObserver

Does Twist Bioscience Corp (TWST) Have What it Takes to be in Your Portfolio Friday?.

Posted: Fri, 31 Mar 2023 07:00:00 GMT [source]

There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “buy” TWST shares. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.

The 7 top four safest investments for a boomer ss with a stock price forecast for TWST stock have an average 12-month price target of $30.43, which predicts an increase of 143.83%. Intraday Data provided by FACTSET and subject to terms of use. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only.

  • Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations.
  • As an investor, you want to buy stocks with the highest probability of success.
  • Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.
  • Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes.

Data may be intentionally delayed pursuant to supplier requirements. News Corp is a global, diversified media and information services company focused on creating and distributing authoritative and engaging content and other products and services. Any hopes of a positive week were dashed on Friday, as the September slump continued and left each of the major indices with slight losses over the five days.

Shareholder Returns

The largest positive contribution comes from its “Creating knowledge” impact, which is false driven by its “Deoxyribonucleic acid ” and “Monoclonal antibodies for research” https://1investing.in/. Twist Bioscience does not have a long track record of dividend growth.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. Raised $75 million in an initial public offering on Wednesday, October 31st 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share.

3 people have added Twist Bioscience to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. 15 people have searched for TWST on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Twist Bioscience has received a 65.93% net impact score from Upright.

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. Independent Non-Employee Director exercised options to buy US$231k worth of stock. 44 employees have rated Twist Bioscience Chief Executive Officer Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among the company’s employees. Sign-up to receive the latest news and ratings for Twist Bioscience and its competitors with MarketBeat’s FREE daily newsletter. The P/E ratio of Twist Bioscience is -3.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

A veteran volatility trader known for nailing the market’s recent twists and turns warns the Fed still needs to suck ‘the wealth effect’ out of stocks – Fortune

A veteran volatility trader known for nailing the market’s recent twists and turns warns the Fed still needs to suck ‘the wealth effect’ out of stocks.

Posted: Thu, 13 Apr 2023 07:00:00 GMT [source]

This means that analysts believe this stock is likely to outperform the market over the next twelve months. Real-time analyst ratings, insider transactions, earnings data, and more. The company’s average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.

0 Comments

Leave a reply

Your email address will not be published.

*

©2024 Smoke Break Media

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account